AbbVie (ABBV) Q3 2026 earnings summary

Executive summary

• Q3 net revenue was $17.404B, up 10.3% reported and 10.5% operational; adjusted diluted EPS was $3.82, versus $1.86 a year earlier.

• Immunology and neuroscience led portfolio growth; FY26 revenue guidance rose by $200M and adjusted EPS guidance increased.

Financial highlights

• GAAP operating earnings were $6.267B versus $1.904B, and GAAP net earnings were $4.218B versus $186M; GAAP diluted EPS was $2.37 versus $0.10.

• Adjusted gross and operating margins were 85.1% and 48.7%; adjusted R&D and SG&A were 13.9% and 21.2% of sales.

• Acquired IPR&D and milestone expense reduced Q3 adjusted diluted EPS by $0.11; adjusted results also excluded $1.669B of intangible amortization and $408M of acquisition and integration costs.

• Nine-month revenue was $49.396B, up 10.9% reported and 10.1% operational; operating cash flow was $14.9B.

Outlook and guidance

• FY26 revenue guidance rose $200M to $67.8B; adjusted EPS guidance increased to $13.95–$13.99, including $0.69 per share of acquired IPR&D and milestone expense incurred through Q3.

• FY immunology sales outlook is $34.9B, including SKYRIZI at $21.8B and RINVOQ at $10.3B; neuroscience outlook is $13B.

• FY oncology sales guidance is $6.6B and aesthetics outlook remains $5B; adjusted operating margin is forecast at ~46.7%.

• Q4 revenue guidance is $18.4B and adjusted EPS guidance is $3.83–$3.87, excluding acquired IPR&D expense that may occur in the quarter.

• 2027 guidance is expected on the Q4 call; management expects top-tier growth, with VRAYLAR IRA pricing beginning in 2027.